Immunoglobulin lambda joining 3 (IGLJ3)

Immunoglobulin lambda joining 3 (IGLJ3) is a gene segment located within the immunoglobulin lambda locus on human chromosome 22. It is one of several *joining (J)* segments that are incorporated, through DNA rearrangement events (V-J recombination), into the structure of the variable region of the immunoglobulin lambda (λ) light chains of antibodies[1][2][3]. J segments do not encode a functional protein by themselves, but instead contribute to antibody diversity during B cell development as part of the rearranged immunoglobulin light chain gene. The IGLJ3 segment, like other J segments, is essential for generating diverse antigen receptors but is not considered a direct therapeutic target, enzyme, receptor, transporter, or druggable protein[1][3]. Key clarifications: - IGLJ3 is a genetic segment within the immunoglobulin lambda joining cluster; it is required for antibody gene rearrangement but is not a protein product or independent biological target[2][3]. - The locus and related gene segments (including IGLJ3) are essential to the immune system’s ability to generate a diverse repertoire of antibodies but have no direct involvement as a drug target, receptor, or therapeutic protein themselves[1][3]. - No known drugs interact directly with J gene segments, and these are not used as biomarkers or therapeutic targets. Diseases associated with this locus generally relate to its structural or regulatory roles, not targetable molecular activity[1]. This entry is considered incorrect as a therapeutic target because IGLJ3 is a DNA segment involved in immunoglobulin gene rearrangement, not a stand-alone protein, receptor, or functional molecule amenable to direct targeting by drugs or diagnostics[1][2][3].

Other names

Immunoglobulin lambda J3Immunoglobulin lambda joining region 3